# REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q2 P&L / Income Statement

- Company: REGENERON PHARMACEUTICALS, INC. (REGN)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-30, accession number 0000872589-26-000025
- Page: https://plicit.ai/financials/regn/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/regn-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 4,290,700,000 US dollars
- **Cost of revenue (calculated)**: 576,500,000 US dollars
- **Gross profit (calculated)**: 3,714,200,000 US dollars
- **Operating expenses (calculated)**: 2,420,700,000 US dollars
- **Income from operations**: 1,293,500,000 US dollars
- **Total other income (expense)**: 234,300,000 US dollars
- **Income before income taxes**: 1,527,800,000 US dollars
- **Income tax expense**: 230,900,000 US dollars
- **Net income**: 1,296,900,000 US dollars
- **Lynozyfic**: 16,500,000 US dollars
- **Other products**: 0 US dollars
- **EYLEA HD And EYLEA - UNITED STATES**: 1,008,500,000 US dollars
- **EYLEA HD - UNITED STATES**: 596,300,000 US dollars
- **Evkeeza - UNITED STATES**: 53,300,000 US dollars
- **EYLEA Net Product Sales - UNITED STATES**: 412,200,000 US dollars
- **Libtayo - UNITED STATES**: 342,600,000 US dollars
- **Libtayo - Rest Of World**: 146,800,000 US dollars
- **Praluent - UNITED STATES**: 74,700,000 US dollars
- **Undisclosed (calculated)**: 1,639,800,000 US dollars
- **Cost of goods sold, collaboration and contract manufacturing**: 576,500,000 US dollars
- **Research and development**: 1,631,600,000 US dollars
- **Acquired in-process research and development**: 127,000,000 US dollars
- **Selling, general, and administrative**: 662,100,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service

- Page: https://plicit.ai/financials/regn/fy2026-q2-income-statement/revenue-by-product-and-service
- Chart image: https://plicit.ai/charts/regn-fy2026-q2-revenue-by-product-and-service-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (Schedule of Net Product Sales). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 4,290,700,000 US dollars
- **Cost of revenue (calculated)**: 576,500,000 US dollars
- **Gross profit (calculated)**: 3,714,200,000 US dollars
- **Operating expenses (calculated)**: 2,420,700,000 US dollars
- **Income from operations**: 1,293,500,000 US dollars
- **Total other income (expense)**: 234,300,000 US dollars
- **Income before income taxes**: 1,527,800,000 US dollars
- **Income tax expense**: 230,900,000 US dollars
- **Net income**: 1,296,900,000 US dollars
- **Libtayo**: 489,400,000 US dollars
- **Other products**: 0 US dollars
- **Lynozyfic**: 16,500,000 US dollars
- **Undisclosed (calculated)**: 3,784,800,000 US dollars
- **Cost of goods sold, collaboration and contract manufacturing**: 576,500,000 US dollars
- **Research and development**: 1,631,600,000 US dollars
- **Acquired in-process research and development**: 127,000,000 US dollars
- **Selling, general, and administrative**: 662,100,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (2)

- Page: https://plicit.ai/financials/regn/fy2026-q2-income-statement/revenue-by-product-and-service-2
- Chart image: https://plicit.ai/charts/regn-fy2026-q2-revenue-by-product-and-service-2-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 4,290,700,000 US dollars
- **Cost of revenue (calculated)**: 576,500,000 US dollars
- **Gross profit (calculated)**: 3,714,200,000 US dollars
- **Operating expenses (calculated)**: 2,420,700,000 US dollars
- **Income from operations**: 1,293,500,000 US dollars
- **Total other income (expense)**: 234,300,000 US dollars
- **Income before income taxes**: 1,527,800,000 US dollars
- **Income tax expense**: 230,900,000 US dollars
- **Net income**: 1,296,900,000 US dollars
- **Net product sales**: 1,642,400,000 US dollars
- **Collaboration revenue**: 2,455,000,000 US dollars
- **Other revenue**: 193,300,000 US dollars
- **Cost of goods sold, collaboration and contract manufacturing**: 576,500,000 US dollars
- **Research and development**: 1,631,600,000 US dollars
- **Acquired in-process research and development**: 127,000,000 US dollars
- **Selling, general, and administrative**: 662,100,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.